AB278524

Anti-Factor I/CFI 抗体 [EPR23948-48]

Anti-Factor I/CFI antibody [EPR23948-48]

RabMAb
Recombinant
詳細を見る

Be the first to review this product! Submit a review

(1 Publication)

Rabbit Recombinant Monoclonal Complement Factor I antibody. Suitable for IP, WB and reacts with Human samples. Cited in 1 publication.

別名を表示する

IF, CFI, Complement factor I, C3B/C4B inactivator

3 Images

Lab

Immunoprecipitation - Anti-Factor I/CFI antibody [EPR23948-48] (AB278524)

Factor I/CFI was immunoprecipitated from 0.35 mg HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate 10 ug with ab278524 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab278524 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/5000 dilution.

Lane 1 : HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate 10 ug

Lane 2 : ab278524 IP in HepG2 whole cell lysate

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of abid in HepG2 whole cell lysate

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 76 seconds

All lanes:

Immunoprecipitation - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524)

Predicted band size: 66 kDa

Observed band size: 50-88 kDa

false

Lab

Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (AB278524)

Blocking and diluting buffer and concentration : 5% NFDM/TBST

Factor I/CFI is a glycoprotein, and de-glycosylation resulted in a decrease of MW (lanes 2 and 4). Different band sizes of CFI heavy chain in liver and HepG2 lysates (lanes 1 and 3) observed may be caused by different glycosylation levels.

Exposure time : 26 seconds.

All lanes:

Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524) at 1/1000 dilution

Lane 1:

Human liver tissue lysate at 20 µg

Lane 2:

Human liver tissue lysate treated with PNGase F at 20 µg

Lane 3:

HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 4:

HepG2 whole cell lysate treated with PNGase F at 20 µg

Secondary

All lanes:

Western blot - VeriBlot for IP Detection Reagent (HRP) (<a href='/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/2000 dilution

Predicted band size: 66 kDa

Observed band size: 40 kDa,50 kDa,75 kDa,88 kDa

false

Lab

Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (AB278524)

Blocking and diluting buffer and concentration : 5% NFDM/TBST

The molecular weight observed is consistent with what has been described in the literature (PMID : 17597211).

Low expression : A549 (PMID : 17548110).

Exposure time : Lanes 1-3 : 15 seconds; Lanes 4-6 : 5.5 seconds.

All lanes:

Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524) at 1/1000 dilution

Lane 1:

HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 2:

A549 (human lung carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 3:

Human liver tissue lysate at 40 µg

Lane 4:

Human lung tissue lysate at 40 µg

Lane 5:

Human small intestine tissue lysate at 40 µg

Lane 6:

Human plasma at 10 µL

Secondary

All lanes:

Western blot - VeriBlot for IP Detection Reagent (HRP) (<a href='/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/1000 dilution

Predicted band size: 66 kDa

Observed band size: 50-88 kDa

false

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR23948-48

アイソタイプ

IgG

キャリアフリー

交差種

Human

アプリケーション

IP, WB

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" }, "Mouse": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" }, "Rat": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" } } }

style

left-column

製品の詳細

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

出荷温度及び保存条件

製品の状態

Liquid

精製方法

Affinity purification Protein A

バッファー組成

Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

出荷温度

Conditional Ambient

短期保存期間

1-2 weeks

短期保存温度

+4°C

長期保存温度

-20°C

分注に関する情報

Upon delivery aliquot

保管に関する情報

Avoid freeze / thaw cycle

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Factor I also known as Complement Factor I (CFI) is a serine protease involved in the complement system. Its molecular mass is approximately 88 kDa consisting of a heavy and a light chain linked by a disulfide bond. This protein is mainly expressed in the liver and circulates in the plasma. Factor I inhibits the complement pathways by cleaving complement components C3b and C4b preventing the formation of C3 and C5 convertases.

Biological function summary

Factor I plays a role in maintaining immune homeostasis by preventing excessive complement activation. It acts within a complex that includes cofactors such as Factor H Complement Factor 4 binding protein (C4BP) and Membrane Cofactor Protein (MCP). These interactions allow Factor I to selectively degrade activated complement components ensuring that complement activity is kept in check to avoid host cell damage.

Pathways

Factor I operates in both the classical and alternative complement pathways. In the classical pathway it regulates C3b and C4b breakdown to control the formation of the C3 convertase. In the alternative pathway Factor I works in conjunction with Factor H to degrade C3b. This regulation is important to prevent runaway activation protecting healthy tissue from complement-mediated damage.

Factor I deficiencies can lead to conditions like atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD). In aHUS insufficient Factor I activity permits unregulated complement activation leading to thrombotic microangiopathy. In AMD aberrant complement activation contributes to retinal damage and degeneration. These conditions illustrate the need for balanced Factor I activity to prevent disease.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

Trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways. Inhibits these pathways by cleaving three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins (PubMed : 17320177, PubMed : 7360115). Essential cofactors for these reactions include factor H and C4BP in the fluid phase and membrane cofactor protein/CD46 and CR1 on cell surfaces (PubMed : 12055245, PubMed : 2141838, PubMed : 9605165). The presence of these cofactors on healthy cells allows degradation of deposited C3b by CFI in order to prevent undesired complement activation, while in apoptotic cells or microbes, the absence of such cofactors leads to C3b-mediated complement activation and subsequent opsonization (PubMed : 28671664).

See full target information CFI

style

left-column

文献 (1)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 13:866330 PubMed35619721

2022

Complement Factor I Variants in Complement-Mediated Renal Diseases.

Applications

Unspecified application

Species

Unspecified reactive species

Yuzhou Zhang,Renee X Goodfellow,Nicolo Ghiringhelli Borsa,Hannah C Dunlop,Stephen A Presti,Nicole C Meyer,Dingwu Shao,Sarah M Roberts,Michael B Jones,Gabriella R Pitcher,Amanda O Taylor,Carla M Nester,Richard J H Smith

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-Factor I/CFI 抗体 [EPR23948-48]

Anti-Factor I/CFI antibody [EPR23948-48]

Immunoprecipitation - Anti-Factor I/CFI antibody [EPR23948-48] (AB278524)

Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (AB278524)

Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (AB278524)

関連する標識済み抗体及び組成の異なる製品 (1)

Key facts

宿主種

クローン性

クローン番号

アイソタイプ

キャリアフリー

交差種

アプリケーション

免疫原

組合せ製品

Assay Kits

Primary Antibodies

Proteins & Peptides

Proteins & Peptides

Primary Antibodies

Reactivity data

製品の詳細

出荷温度及び保存条件

製品の状態

精製方法

バッファー組成

出荷温度

短期保存期間

短期保存温度

長期保存温度

分注に関する情報

保管に関する情報

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (1)

Abcam product promise